1. Home
  2. SBR vs CTMX Comparison

SBR vs CTMX Comparison

Compare SBR & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sabine Royalty Trust

SBR

Sabine Royalty Trust

HOLD

Current Price

$75.33

Market Cap

1.1B

Sector

Energy

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$4.39

Market Cap

977.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBR
CTMX
Founded
1982
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
977.1M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
SBR
CTMX
Price
$75.33
$4.39
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$12.10
AVG Volume (30 Days)
41.1K
11.2M
Earning Date
05-14-2026
05-11-2026
Dividend Yield
6.51%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,201,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18.75
P/E Ratio
$12.77
$22.58
Revenue Growth
N/A
N/A
52 Week Low
$62.23
$0.53
52 Week High
$84.39
$8.21

Technical Indicators

Market Signals
Indicator
SBR
CTMX
Relative Strength Index (RSI) 55.02 45.84
Support Level $75.29 $3.89
Resistance Level $77.08 $4.54
Average True Range (ATR) 1.73 0.29
MACD -0.10 -0.00
Stochastic Oscillator 65.39 41.14

Price Performance

Historical Comparison
SBR
CTMX

About SBR Sabine Royalty Trust

Sabine Royalty Trust formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: